Synthesis method of PSMA-11 polypeptide
Through solid-phase synthesis method and reverse-phase high-performance liquid chromatography purification method, the safety hazards of three phosgene or phosgene use in the synthesis of PSMA-11 polypeptides in the prior art are solved, and high safety and high purity PSMA- 11 polypeptide synthesis, suitable for large-scale production and economical value.
Patent Information
- Application Number
- CN202410926886.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-05
AI Technical Summary
In the existing synthesis methods of PSMA-11 polypeptides, the use of triprophosgene or phosgene for UREA coupling modification poses a major safety hazard, affecting the environment and human health.
By using solid phase synthesis method, the carrier resin is combined with N,N-dimethylformamide, Fmoc-GLU(OtBu)-OH, activator and condensing agent, from the C-terminus to the N-terminus according to the amino acid sequence of the PSMA-11 polypeptide The use of triphosgene or phosgene was cleaved and cleaved using trifluoroacetic acid, followed by reverse phase high performance liquid chromatography.
It has achieved high safety synthesis of PSMA-11 polypeptide, which is simple to operate, short cycle, low cost, few by-products and high purity. It is suitable for large-scale production, with significant economic value and wide application prospects.
Smart Images

Figure BDA0004938466790000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of polypeptide synthesis, and in particular relates to a method for synthesizing a PSMA-11 polypeptide. Background Art
[0002] PSMA-11 is a positron emission tomography (PET) tracer used to detect the recurrence and metastasis of prostate cancer by binding to the extracellular region of prostate-specific membrane antigen (PSMA). PSMA (prostate-specific membrane antigen) is a transmembrane protein that is highly expressed in almost all prostate cancer cells, 100 to 1000 times higher than normal cells, and its expression increases with the increase of tumor stage and grade, which makes PSMA an ideal diagnostic and therapeutic target. PSMA-11 is a dimerized PSMA inhibitor that can bind to PSMA and inhibit its function. It is used to treat prostate cancer. PSMA PET / CT imaging is of great value in the early diagnosis, disease assessment, staging and re-staging, adjuvant therapy, prognosis assessment and follow-up of prostate cancer.
[0003] The PSMA-11 structure is as follows:
[0004]
[0005] PSMA-11 knot sequence: LYS(ACP-HBED-CC)-UREA-GLU.
[0006] However, in the prior art, the synthesis of PSMA-11 mostly uses triphosgene or phosgene for UREA coupling modification, but this synthesis method has great safety risks. Triphosgene or phosgene has a great impact on the human body and the environment. Summary of the invention
[0007] The object of the present invention is to provide a method for synthesizing a PSMA-11 polypeptide, which avoids the use of triphosgene or phosgene for UREA coupling modification and has high safety.
[0008] The purpose of the present invention can be achieved through the following technical solutions:
[0009] A method for synthesizing a PSMA-11 polypeptide comprises the following steps:
[0010] Step 1: Starting with a carrier resin, the carrier resin is added to a solid phase reaction column, washed and swollen with N,N-dimethylformamide to obtain a carrier resin reaction column, and then Fmoc-GLU(OtBu)-OH is dissolved with dichloromethane and mixed with an activator and a condensing agent, and added to the carrier resin reaction column for condensation reaction to couple the solid phase carrier resin and the N-terminal Fmoc-protected Fmoc-GLU(OtBu)-OH, washed, blocked, and washed to obtain Fmoc-GLU(OtBu)-carrier resin;
[0011] The usage ratio of Fmoc-GLU(OtBu)-OH, dichloromethane, activator and condensation agent is 8.56g:20mL:20g:4.05g.
[0012] Step 2: According to the amino acid sequence of the PSMA-11 polypeptide, the monomers are sequentially coupled with the Fmoc-GLU (OtBu)-carrier resin by solid phase synthesis in the coupling order from the C-terminus to the N-terminus to obtain the PSMA-11-carrier resin;
[0013] Step 3: The PSMA-11-carrier resin is sequentially cleaved using a mixed solution and trifluoroacetic acid to obtain a PSMA-11 crude peptide;
[0014] Step 4: Purify and freeze-dry the crude PSMA-11 peptide to obtain the finished PSMA-11 peptide.
[0015] Furthermore, in step one, the carrier resin is 2-Chlorotrophy lchl ori de resin and the degree of substitution is 1 mmol / g.
[0016] Furthermore, Fmoc is 9-fluorenylmethoxycarbonyl, and Fmoc is connected to the amino group or to the nitrogen atom on the carbon atom to which the carboxyl group is connected.
[0017] Furthermore, the monomer is NH2-LYS(Fmoc)-OTBU, Fmoc-ACP-OH, HBED-CC-tris (ter-buty l ester) with N-terminal Fmoc protection and side chain protected by urea group.
[0018] Furthermore, the coupling sequence from the C-terminus to the N-terminus in step 2 is as follows:
[0019] Fmoc-GLU(OtBu)-OH,NH2-LYS(Fmoc)-OTBU,Fmoc-ACP-OH,HBED-CC-tr is(ter-buty l ester)
[0020] Furthermore, the specific steps of the solid phase synthesis method in step 2 are as follows:
[0021] Step 1: Use DBLK reagent to remove Fmoc from Fmoc-GLU(OtBu)-carrier resin to obtain NH2-GLU(OtBu)-carrier resin;
[0022] Step 2: Under the condition of adding an activator and a condensing agent, NH2-GLU(tBu)-carrier resin and N,N'-disuccinimidyl carbonate are subjected to a condensation reaction;
[0023] Step 3: According to the coupling order from the C-terminus to the N-terminus of the PSMA-11 polypeptide amino acid sequence, steps 1 and 2 are repeated, and NH2-LYS(Fmoc)-OTBU, Fmoc-ACP-OH and HBED-CC-tris(ter-buty l ester) are used to replace N,N'-disuccinimidyl carbonate for condensation reaction until the PSMA-11-carrier resin is synthesized.
[0024] Furthermore, the DBLK reagent is a mixture of piperidine and N,N-dimethylformamide in a volume ratio of 1:3.
[0025] Furthermore, the activator is 1,3-diisopropylcarbodiimide, the condensation agent is 1-hydroxybenzotriazole, and the condensation reaction time is 2 hours.
[0026] Furthermore, the mixed solution in step three is a mixture of trifluoroacetic acid, ultrapure water, anisole and thioanisole in a mass ratio of 90:5:4:1.
[0027] Furthermore, the specific steps of purification in step 4 are as follows:
[0028] Reverse-phase high performance liquid chromatography was used with reverse-phase octadecylsilane as the stationary phase, the column temperature was 35° C., the mobile phase A was a 0.1% trifluoroacetic acid aqueous solution, the mobile phase B was acetonitrile, the mobile phase A and the mobile phase B were eluted in an isocratic gradient at a volume ratio of 70:30, the flow rate was 70-80 mL / min, and the detection wavelength was 214 nm.
[0029] Beneficial effects of the present invention:
[0030] The present invention provides a method for synthesizing a PSMA-11 polypeptide by a solid phase synthesis method, which has simple operation, short synthesis cycle, and low cost. Compared with the preparation of the PSMA-11 polypeptide by UREA coupling modification using triphosgene or phosgene, the method has high safety, reduced generation of waste liquid, easy post-treatment, few by-products, and high product yield. The purity of the PSMA-11 polypeptide is 96%, and the yield is 95%, which is conducive to the large-scale production of the PSMA-11 polypeptide and has considerable economic value and broad application prospects. DETAILED DESCRIPTION
[0031] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Example 1: This example provides a method for synthesizing a PSMA-11 polypeptide, comprising the following steps:
[0033] Step 1: Starting with 20 g of 2-Chlorotylic chloride resin carrier resin with a degree of substitution of 1 mmol / g, the 2-Chlorotylic chloride resin carrier resin is added to a solid phase reaction column, washed and swollen with N,N-dimethylformamide to obtain a carrier resin reaction column. The degree of substitution refers to the amount of substance loaded per unit amount of resin.
[0034] 8.56 g of Fmoc-GLU(OtBu)-OH was dissolved in 20 mL of dichloromethane and mixed with 20 g of 1,3-diisopropylcarbodiimide as an activating agent and 4.05 g of 1-hydroxybenzotriazole as a condensing agent, and added to a carrier resin reaction column for condensation reaction for 2 h to couple the solid phase carrier resin and the N-terminal Fmoc-protected Fmoc-GLU(OtBu)-OH. After washing with N,N-dimethylformamide, 8 mL of methanol was added to seal for 1 h, and then washed with N,N-dimethylformamide to obtain Fmoc-GLU(OtBu)-carrier resin.
[0035] Fmoc is 9-fluorenylmethoxycarbonyl, and Fmoc is connected to the amino group or to the nitrogen atom on the carbon atom to which the carboxyl group is connected.
[0036] Step 2: piperidine and N, N-dimethylformamide were mixed in a volume ratio of 1:3 to obtain DBLK reagent. According to the amino acid sequence of PSMA-11 polypeptide, the PSMA-11-carrier resin was synthesized by solid phase synthesis in the coupling order from C-terminus to N-terminus, i.e., Fmoc-GLU(OtBu)-OH, NH2-LYS(Fmoc)-OTBU, Fmoc-ACP-OH, HBED-CC-tr is(ter-buty l ester).
[0037] 1. First, add 10g of Fmoc-GLU (OtBu)-carrier resin to the solid phase reaction column, wash it twice with N, N-dimethylformamide, swell it with N, N-dimethylformamide for 20 minutes, and then wash it with DBLK reagent to remove Fmoc from the Fmoc-GLU (OtBu)-carrier resin. Then use the ninhydrin method to detect the color of the resin. If the resin has color, it means that Fmoc has been completely removed.
[0038] Dissolve 5.12g of N,N'-disuccinimidyl carbonate and 20g of N,N-diisopropylethylamine in a mixed solution of dichloromethane and N,N-dimethylformamide in a volume ratio of 1:1, then add it to the solid phase reaction column, react for 2h at 22.5±2.5℃, and use the ninhydrin method to determine the reaction end point. If the resin in the solid phase reaction column is colorless and transparent, the reaction is complete. If the resin is colored, it means that the reaction is incomplete. Continue the coupling reaction for 1h under the same conditions. This standard is applicable to the ninhydrin method for determining the reaction end point in the subsequent steps.
[0039] 2. Dissolve 14.4 g NH2-LYS(Fmoc)-OTBU, 20 g 1,3-diisopropylcarbodiimide and 4.05 g 1-hydroxybenzotriazole in a mixed solution of dichloromethane and N,N-dimethylformamide in a volume ratio of 1:1, and then add them to the solid phase reaction column in step 1. React for 2 h at 22.5±2.5°C. Use the ninhydrin method to determine the reaction endpoint. After the reaction is complete, use DBLK reagent to wash and remove Fmoc. Wash with N,N-dimethylformamide 4 times and dichloromethane 2 times. Use the ninhydrin method to detect the color of the resin. If the resin has color, it means that Fmoc has been removed.
[0040] 3. Dissolve 10.59g Fmoc-ACP-OH, 20g 1,3-diisopropylcarbodiimide and 4.05g 1-hydroxybenzotriazole in a mixed solution of dichloromethane and N,N-dimethylformamide in a volume ratio of 1:1, and then add it to the solid phase reaction column in step 2. React for 2h at 22.5±2.5℃. Use the ninhydrin method to determine the reaction end point. After the reaction is complete, use DBLK reagent to wash and remove Fmoc. Wash with N,N-dimethylformamide 4 times and dichloromethane 2 times. Use the ninhydrin method to detect the color of the resin. The resin has color, indicating that Fmoc has been removed.
[0041] 4. Dissolve 14.01 g HBED-CC-tris (ter-buty l ester), 20 g 1,3-diisopropylcarbodiimide and 4.05 g 1-hydroxybenzotriazole in a mixed solution of dichloromethane and N,N-dimethylformamide in a volume ratio of 1:1, and then add them to the solid phase reaction column in step 3. React for 2 h at 22.5±2.5°C. Use the ninhydrin method to determine the reaction end point. After the reaction is complete, PSMA-11-carrier resin is obtained.
[0042] The PSMA-11-carrier resin in step 2 was washed twice with methanol, dried in vacuo to constant weight, and weighed. The mass of the dried PSMA-11-carrier resin was 19.2 g (weight gain rate was 92.0%).
[0043] Step 3: Trifluoroacetic acid, ultrapure water, anisole and anisole thioether are mixed in a mass ratio of 90:5:4:1 to prepare a mixed solution, and the PSMA-11-carrier resin is cut and cracked using the mixed solution and trifluoroacetic acid. The specific method of cutting and cracking is as follows: 19.2 g of the dried PSMA-11-carrier resin in step 2 is added to a three-necked flask with a volume of 1 L, and then 200 mL of the mixed solution is added, and the reaction is carried out at 22.5±2.5°C for 2 hours, and the filtrate is filtered under reduced pressure, and the filtrate is collected. The residue is washed with trifluoroacetic acid, and the washing liquid and the filtrate are combined. After precipitation and centrifugation, the precipitate is washed with ice ether 5 times (2L / time), and dried under reduced pressure to obtain PSMA-11 crude peptide. According to high performance liquid chromatography analysis, the purity of PSMA-11 crude peptide is 87.9%.
[0044] Step 4: The crude PSMA-11 peptide in step 3 was subjected to reverse-phase high performance liquid chromatography, with reverse-phase octadecylsilane as the stationary phase, the column temperature was 35° C., the mobile phase A was a trifluoroacetic acid aqueous solution with a volume fraction of 0.1%, the mobile phase B was acetonitrile, the mobile phase A and the mobile phase B were eluted in an isocratic manner at a volume ratio of 70:30, the flow rate was 75±5 mL / min, the detection wavelength was 214 nm, the target peak fractions were collected, and the concentrated and freeze-dried fractions were obtained by liquid nitrogen to obtain a PSMA-11 polypeptide product with a mass of 8.3 g, a purity of 96%, and a yield of 95%.
[0045] It should be noted that, in this article, terms such as "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or apparatus.
[0046] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for synthesizing a PSMA-11 polypeptide, characterized in that: The steps include: Step 1: Starting with a carrier resin, the carrier resin is added to a solid phase reaction column, washed and swollen with N,N-dimethylformamide to obtain a carrier resin reaction column, and then Fmoc-GLU(OtBu)-OH is dissolved with dichloromethane and mixed with an activator and a condensing agent, added to the carrier resin reaction column for condensation reaction, washed, sealed, and washed to obtain Fmoc-GLU(OtBu)-carrier resin; Step 2: According to the amino acid sequence of PSMA-11 polypeptide, PSMA-11-carrier resin is synthesized by solid phase synthesis in the coupling order from C-terminus to N-terminus; Step 3: The PSMA-11-carrier resin is sequentially cleaved using a mixed solution and trifluoroacetic acid to obtain a PSMA-11 crude peptide; Step 4: Purify and freeze-dry the crude PSMA-11 peptide to obtain the finished PSMA-11 peptide.
2. The method for synthesizing a PSMA-11 polypeptide according to claim 1, characterized in that: The carrier resin in step 1 is 2-Chlorotrityl chloride resin, and the degree of substitution is 1 mmol / g.
3. The method for synthesizing a PSMA-11 polypeptide according to claim 1, characterized in that: The usage ratio of the Fmoc-GLU(OtBu)-OH, dichloromethane, activator and condensation agent is 8.56 g:20 mL:20 g:4.05 g.
4. The method for synthesizing a PSMA-11 polypeptide according to claim 1, characterized in that: The Fmoc is 9-fluorenylmethoxycarbonyl.
5. The method for synthesizing a PSMA-11 polypeptide according to claim 1, characterized in that: The specific steps of the solid phase synthesis method described in step 2 are as follows: Step 1: Use DBLK reagent to remove Fmoc from Fmoc-GLU(OtBu)-carrier resin to obtain NH2-GLU(OtBu)-carrier resin; Step 2: Under the condition of adding an activator and a condensing agent, NH2-GLU(tBu)-carrier resin and N,N'-disuccinimidyl carbonate are subjected to a condensation reaction; Step 3: According to the coupling order from the C-terminus to the N-terminus of the PSMA-11 polypeptide amino acid sequence, steps 1 and 2 are repeated, and different monomers are used to replace N,N'-disuccinimidyl carbonate for condensation reaction, until the PSMA-11-carrier resin is synthesized.
6. The method for synthesizing a PSMA-11 polypeptide according to claim 5, characterized in that: The monomers are NH2-LYS(Fmoc)-OTBU, Fmoc-ACP-OH and HBED-CC-tris(ter-buty lester).
7. The method for synthesizing a PSMA-11 polypeptide according to claim 5, characterized in that: The DBLK reagent is prepared by mixing piperidine and N,N-dimethylformamide in a volume ratio of 1:
3.
8. The method for synthesizing a PSMA-11 polypeptide according to claim 5, characterized in that: The activator is 1,3-diisopropylcarbodiimide, the condensation agent is 1-hydroxybenzotriazole, and the condensation reaction time is 2 hours.
9. The method for synthesizing a PSMA-11 polypeptide according to claim 1, characterized in that: The mixed solution in step 3 is prepared by mixing trifluoroacetic acid, ultrapure water, anisole and thioanisole in a mass ratio of 90:5:4:
1.
10. The method for synthesizing a PSMA-11 polypeptide according to claim 1, characterized in that: The specific steps of purification described in step 4 are as follows: Reverse-phase high performance liquid chromatography was used with reverse-phase octadecylsilane as the stationary phase, the column temperature was 35° C., the mobile phase A was a 0.1% trifluoroacetic acid aqueous solution, the mobile phase B was acetonitrile, the mobile phase A and the mobile phase B were eluted in an isocratic gradient at a volume ratio of 70:30, the flow rate was 70-80 mL / min, and the detection wavelength was 214 nm.
Citation Information
Patent Citations
Prostatic cancer PET (polyethylene terephthalate) diagnostic reagent 68Ga-HBBED-ANCP-PSMA, preparation method thereof and application of diagnostic reagent
CN110317151A
Compound targeting prostate specific membrane antigen, and application of compound
CN112190722A
Preparation method of parent of targeted PSMA and derivative thereof
CN115925586A
Synthesis of prostate specific membrane antigen (PSMA) ligands
CN116438161A
Method for synthesizing liraglutide
CN116730902A
Cited By
Synthesis method of antifreeze glycopeptide polypeptide
CN119978062A
